Core Viewpoint - Medtronic is positioning itself as a strong player in the robotic surgery market while maintaining a solid foundation in the medical device industry, with a focus on growth and innovation. Company Overview - Medtronic has a forward-looking price-to-earnings (P/E) ratio of 16.3, slightly below its five-year average of 16.7, indicating a compelling valuation [2] - The company has a dividend yield of 2.9% and has increased its dividend for 48 consecutive years, showcasing its commitment to returning value to shareholders [4] - Medtronic's payout ratio is approximately 79%, suggesting room for further dividend growth and sustainability [5] Business Operations - Medtronic operates in various treatment areas, including surgery, endoscopy, cardiac ablation, neurovascular disorders, neuromodulation, pelvic health, gastric therapies, and cranial and spinal technologies [5] - The company has over 41,000 active patent matters and employs more than 13,600 scientists and engineers across 150 countries [6] - Medtronic treats over 70 health conditions and is conducting more than 174 active clinical trials, with an annual research and development expenditure of around $2.7 billion [6] Recent Performance - In its recently reported third quarter, Medtronic achieved an 8.7% year-over-year revenue increase and received FDA approval for its Hugo robotic surgery system [8] - CEO Geoff Martha emphasized the company's focus on unlocking new markets and investing in high-growth opportunities to accelerate performance [8] Strategic Moves - Medtronic is spinning off its diabetes division, aiming for a valuation close to $8 billion, to concentrate on faster-growing business segments [7]

On Feb. 5, 2026, Rockport Wealth LLC disclosed a new position in First Trust RBA American Industrial Renaissance ETF (NASDAQ:AIRR). What happened According to a Securities and Exchange Commission (SEC) filing dated Feb. 5, 2026, Rockport Wealth LLC opened a new position in the First Trust RBA American Industrial Renaissance ETF purchasing 97,377 shares. The value of the position at quarter end was $9.57 million, reflecting the initial purchase and valuation of the stake. What else to know This was a n ...

Group 1 - Workday, Inc. is identified as a potentially undervalued stock, trading at less than 15 times this year's earnings estimates, with an expected growth rate of 18% despite a 43% decline from its highs [1] - The company provides cloud-based applications for managing financial processes, human resources, and business planning [3] - Polen Capital Management exited its position in Workday due to decelerating revenue growth and challenges in its core human capital management business, which is facing cyclical headwinds [3] Group 2 - There is a belief that certain AI stocks may offer greater upside potential and carry less downside risk compared to Workday [4]

Polen Capital Management Llc released its "Polen Focus Growth Strategy" Q4 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, the Polen Focus Growth strategy delivered a -1.37% gross return, underperforming the Russell 1000 Growth Index (+1.12%) and the S&P 500 (+2.66%), as concentrated mega‑cap leadership and AI valuation concerns drove market volatility. The fund faced headwinds from market rotation and valuation pressures but remained disciplined in its investment approach, fo ...

Polen Capital Management Llc released its "Polen Focus Growth Strategy" Q4 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, the Polen Focus Growth strategy delivered a -1.37% gross return, underperforming the Russell 1000 Growth Index (+1.12%) and the S&P 500 (+2.66%), as concentrated mega‑cap leadership and AI valuation concerns drove market volatility. The fund faced headwinds from market rotation and valuation pressures but remained disciplined in its investment approach, fo ...

Medical devices on clinic table, echoing Abbott's diagnostics and devices ahead of healthcare earnings. Key Points An acceleration from last quarter's 4% year-over-year growth in nutrition segment sales could help boost Abbott Laboratories' revenue performance. Intuitive Surgical's preliminary fourth-quarter earnings results led to a modest dip in share price, perhaps due to middling forecasted da Vinci procedure growth for 2026. Still, overall adoption and revenue growth rates remain high, and the tem ...

Terms of Use Privacy Notice Accessibility About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Checkup Stock Quotes Stock Market Today The Big Picture My Stock Lists IBD Live Leaderboard SwingTrader MarketSurge IBD Digital MarketDiem The Wall Street Journal Barron's MarketWatch Dow Jones Smart Money Connect With Us On stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any speci ...

Market Overview - The U.S. stock market is experiencing a consolidation phase after a year of significant breakthroughs, with the Dow closing at 48,378.13, down 83.80 points or 0.17% [6][12] - The S&P 500 settled at 6,902.11, off 3.63 points or 0.05%, and the NASDAQ ended at 23,460.62, slipping 13.73 points or 0.06% [6][12] Federal Reserve Insights - The Federal Reserve's December meeting minutes are anticipated to reveal divisions within the FOMC, following a 9-3 vote for the third consecutive interest rate cut, the highest dissent in six years [1] - The internal debate on inflation versus a cooling labor market will influence borrowing costs in 2026, with expectations for a pause until April [1] AI Sector Developments - The AI boom's "picks-and-shovels" phase is evolving, with semiconductor companies like Nvidia (NVDA) seeing a 39% stock rise, while Palantir (PLTR) and AMD surged 143% and 78%, respectively [2] - Analysts suggest future gains will come from companies effectively applying AI to enhance corporate earnings, shifting focus towards software and enterprise applications [2] Pharmaceutical Sector Highlights - Eli Lilly (LLY) achieved a historic $1 trillion market cap, with a 40% gain in 2025 driven by the success of Zepbound, and plans to launch orforglipron in Q2 2026 [3] - Johnson & Johnson (JNJ) matched Lilly's gains through a medtech turnaround, preparing to submit its Ottava surgical robot for FDA approval in early 2026 [3] Stock Performance - Merck (MRK) is emerging as a top pick for 2026, upgraded to "outperform" by BMO Capital Markets due to its strengthening pipeline ahead of the 2028 Keytruda patent cliff [4][12] - Ekso Bionics (EKSO) saw a significant breakout, rising 102.08% to $11.03, following news of Applied Digital's plans to spin out its cloud business [7] - Cemtrex, Inc. (CETX) reported a return to operating profitability with $76.5 million in revenue, a 14% year-over-year increase, leading to a 22.99% stock rise [11] Precious Metals Movement - Silver prices surged to $77.3285 per ounce, up $5.1885 or 7.19%, reflecting increased safe-haven demand amid equity market reassessments [9][10] - Gold prices climbed to $4,366.76 per ounce, gaining $34.78 or 0.80%, indicating continued investor demand for stability amid market volatility [10]

Group 1: Dick's Sporting Goods - Dick's Sporting Goods, Inc. is currently down 11% from its highs and trades at 11 times earnings [1] - The company reported third-quarter sales of $4.168 billion, reflecting a 36.3% year-over-year increase, surpassing the expected $3.546 billion [2] - Dick's completed its acquisition of Foot Locker in September, with plans to improve the latter's performance [1] Group 2: Intuitive Surgical - Intuitive Surgical, Inc. shares rose 0.9% to close at $561.89 [4] - Truist Securities analyst Richard Newitter maintained a Buy rating on Intuitive Surgical and raised the price target from $620 to $650 [3] Group 3: Toast, Inc. - Toast, Inc. shares rose 3.2% to close at $36.62 [4] - JPMorgan analyst Tien-Tsin Huang upgraded Toast from Neutral to Overweight, maintaining a price target of $43 [3]

Core Viewpoint - Medtronic has had a strong year despite tariff challenges, with positive financial results and a bright outlook for the next year [1][2] Financial Performance - Medtronic's market capitalization stands at $128 billion, with a gross margin of 59.95% and a dividend yield of 2.82% [7] - The company reported trailing-12-month revenue of $34.76 billion, with potential revenue from urologic procedures estimated at $835 million if it captures a 10% market share of Intuitive Surgical's $8.35 billion revenue from that segment [7] Product Development - Medtronic's Hugo system, a robotic-assisted surgery device, has received U.S. regulatory clearance for urologic procedures, marking a significant milestone for the company [6] - The RAS market is underpenetrated, with fewer than 5% of eligible surgeries currently performed robotically, indicating substantial growth potential for Medtronic's Hugo system [5][8] Competitive Landscape - The Hugo system will compete with Intuitive Surgical's da Vinci system, which is well-established in the urology market, representing a significant challenge for Medtronic [6] - Convincing healthcare facilities to adopt the Hugo system over the da Vinci system will require time and effort [6] Long-term Growth Potential - Medtronic plans to seek additional indications for the Hugo system beyond urology, which could drive future procedure volume growth [8] - The aging global population is expected to fuel growth in the healthcare sector, benefiting Medtronic in the long run [9] Dividend Policy - Medtronic has increased its dividend for 48 consecutive years, positioning itself to become a Dividend King in the near future [11] - The company's strong dividend program is attractive to long-term income-seeking investors [10][11]